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Patients that have failed therapy for Helicobacter pylori (H. pylori) infection are incompletely
characterized. The aim of this study was to characterize a H. pylori treatment resistant
cohort compared to the cohorts of newly diagnosed, earlier eradicated and non-infected.
Material and methods
Patients were selected from routine referrals to the Endoscopy units at three different Nor-
wegian hospitals. In all four cohorts, gastric biopsies were scored according to the Sydney
classification, and symptoms according to the Gastrointestinal Symptom Rating Scale
score, including sub-scores for upper gastrointestinal symptoms and functional bowel symp-
toms. Patients in the H. pylori resistant group were treated with a triple therapy regimen that
consisted of levofloxacin, amoxicillin and a proton pump inhibitor.
Results
We included 185 patients, 42 H. pylori treatment resistant, 50 newly diagnosed, 61 previ-
ously H. pylori eradicated and 32 never infected. The treatment-resistant cohort had higher
scores for upper gastrointestinal symptoms and functional bowel symptoms compared to
the other groups except for the group being never H. pylori infected. The H. pylori resistant
patients had lower Sydney scores than patients with newly diagnosed H. pylori infection.
The triple combination showed a high efficacy of 91% to eradicate H. pylori.
Conclusions
Patients with treatment-resistant H. pylori infection had more gastrointestinal symptoms, but
a lower Sydney score than patients with newly diagnosed infection. A treatment regimen
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including levofloxacin showed a high efficacy in eradicating H. pylori in patients that previ-
ously had failed eradication treatment.
Introduction
Helicobacter pylori (H. pylori) has been identified as the main pathogenic factor for gastric and
duodenal peptic ulcer.[1,2] Treatment of H. pylori infection cures most of the patients with
ulcer, and the disease is no longer a chronically recurrent and disabling condition in Western
world. However, in approximately 50% of the population worldwide, the infection is still a
great problem, especially in underdeveloped countries.[3,4]
Initially, the most effective eradication regimes gave an efficacy >90%.[5] Unfortunately,
during the 30 years of treatment one has observed a growing antimicrobial resistance of H.
pylori[6], including resistance to clarithromycin and metronidazole, proposed to be a conse-
quence of increased antibiotic use in the general population. Clarithromycin resistance has
especially been of major negative impact as it was a main constituent of the recommended first
line triple therapy. Metronidazole resistance is highly prevalent but is possible to overcome to
some extent.[7] Thus, an increasing prevalence of resistance has been observed.[8,9] In areas
with high occurrence of both clarithromycin and metronidazole resistance, a bismuth-con-
taining quadruple therapy is recommended.[10] Despite this, a cohort of patients with treat-
ment-resistant H. pylori has accumulated even in areas with low prevalence of antibiotic
resistance, like Norway.[9] These patients will have a persistent gastric inflammation and a
risk of recurrent ulcer disease and gastric cancer. There are few reports of the clinical or micro-
biological characteristics of this cohort, but some data has been presented in the search for a
new effective antibiotic therapy, including levofloxacin.[11–13]
The goal of this study was to characterize a cohort with treatment-resistant H. pylori infec-
tion, and make clinical comparisons to patients with newly diagnosed H. pylori infection, pre-
viously successfully eradicated H. pylori, and a non-infected cohort. Finally, we wanted to
evaluate the response to treatment with levofloxacin.
Materials and methods
Study population, enrolment and patient flow
Patients were recruited in the period 1990–2012 for screening in the Chronical Infection of
Helicobacter Pylori (CRIHEP) study from three different gastrointestinal units at Norwegian
hospitals: University Hospital of North Norway, Tromsø; Vestre Viken Hospital, Ringerike;
and Vestre Viken Hospital, Drammen; Norway.
Four groups were invited to participate: The treatment-resistant H. pylori group (n = 42)
were patients who had two or more unsuccessful treatment attempts for H. pylori infection.
They were selected from medical records from 1990 to 2012 at the three different hospitals,
and were invited to participate by a mail request. Responders were included after a new gas-
troscopy examination. The three additional patient groups were outpatients referred to the
Endoscopy unit for gastroscopy: The newly diagnosed H. pylori infection group (n = 50) were
included after positive findings of H. pylori infection at the endoscopic examination, the group
of previously successfully treated H. pylori infection 5–20 years ago (n = 61), and the group of
patients without any diagnosed H. pylori infection ever (n = 32) also underwent upper endos-
copy. Patients with severe disease and those who were non-compliant were excluded.
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Biopsies were obtained at endoscopy from the gastric corpus and pyloric antrum for histo-
logical examination and H. pylori rapid urease test.
Patients in the treatment-resistant H. pylori group were treated with oral omeprazole 20 mg
b.i.d, amoxicillin 1 g b.i.d. and levofloxacin 500 mg b.i.d. for 10 days. Those with allergy to pen-
icillin received metronidazole 500 mg t.i.d instead of amoxicillin.
Patients with previously untreated H. pylori infection and findings of peptic ulcer, erosive
gastritis and/or erosive duodenitis were treated with oral omeprazole 20 mg b.i.d., amoxicillin
1 g b.i.d. and clarithromycin 500 mg b.i.d. for seven days. In patients with allergy to penicillin,
metronidazole was used instead of amoxicillin as described above.
All subjects that were given treatment for H. pylori infection underwent a follow-up gastros-
copy after 3–6 months upon which biopsies were obtained for the various examinations
described above.
All patients gave an oral and written consent before enrolment in the study. The study was
approved by the Regional Committee for Medical and Health Research Ethics (REC-North,
ID:2009/2176-11), including approved the storage of biological material.
Symptom scores
All patients filled out the validated Gastrointestinal Symptoms Rating Scale (GSRS) question-
naire.[14] The GSRS includes 15 questions about symptoms where the answers are rated on a
7-graded scale, 1 representing absence of symptoms and 7 most severe symptoms.
To compare the gastrointestinal complaints among the four groups, comparisons were
made between the various dimensions of the GSRS score, and yes/no according to reflux dis-
ease, dyspepsia and functional bowel symptoms according to their definitions.
For upper gastrointestinal symptoms, the questions were divided into 5 clinically relevant
dimensions of the GSRS: abdominal pain, indigestion (increased flatus), reflux, diarrhoea and
constipation, and the total score based on a study of patients referred to upper endoscopy for
dyspepsia according to Dimenas et al. and Reviecki et al.[15,16] (Table 2)
The GSRS questionnaire defines ‘‘reflux syndrome” by asking about ‘‘heartburn” or ‘‘acid
reflux”. The resulting ‘‘reflux syndrome” score is defined as the mean score of 2 or more of the
two items heart burn and acid reflux in GSRS registration according to the references, and also
to the Montreal definition from 2006 (Table 3).[14–17] The questions defining dyspepsia were
the GSRS dimensions: “Have you had abdominal pain located in the upper abdomen for at
least one week”, and “Have you ever had heartburn or acid regurgitation almost daily for at
least one week”. A positive answer to at least one of the questions defined dyspepsia as used by
Asfeldt et al.[18] (Table 3)
The dimensions most relevant for functional bowel symptoms (FBS) were the ten GSRS
questions: abdominal pain, hunger discomfort, borborygmus, abdominal distension, flatu-
lence, constipation, diarrhea, loose stool, urgency and incomplete evacuation. These are the
GSRS dimensions that closest resemble irritable bowel disease and has been developed and val-
idated by Wicklund et al.[19] A cut-off value of�22 defined a positive diagnosis of functional
bowel symptoms based on best comparison (κ = 0.535) described in a previous study from our
research group.[20] (Table 3).
Registrations and analyses
Clinical data including ongoing medication were registered. Biopsies were examined with the
rapid urease test for on-site H. pylori diagnosis. Histological examination (hematoxylin-eosin
staining) including detection was performed by one person (SWS) for H. pylori diagnosis and
Sydney classification. A positive H. pylori status was based on a positive result for at least one
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of the two tests (H. pylori rapid -urease test and histological test). Moreover, a negative H.
pylori status was indicated when both tests were negative.
Statistics
Statistical analyses were performed to evaluate difference between H. pylori groups in upper
gastrointestinal symptoms defined by mean score of the five dimensions of GSRS question-
naire. For analyzing differences between two groups, pairwise Mann-Whitney tests were per-
formed. As a global test for testing differences between groups a non-parametric method,
Kruskal-Wallis one-way ANOVA was performed.
To detect potential confounders for reflux, dyspepsia and functional bowel syndrome
symptoms, variables were tested in a logistic regression model using an Omnibus logistic
regression model. The following variables were tested: H. pylori, sex, age, body mass index,
snuff and smoking habits, and use of platelet inhibitors, NSAIDs, PPI, H2 blockers as well as
H. pylori. Variables with p-values�0.10 were included in the multivariate models. Multivariate
analyses were stratified for sex and the use of PPI and H2 blockers.
All statistical analyses was carried out in IBM SPSS Statistics 24 (IBM Corporation,
Armonk, New York, USA).
Results
Patients included
A total of 185 patients, 165 in Tromsø, 18 in Drammen and 2 in Hønefoss, were included in
the study. The baseline characteristics of the four study groups are shown in Table 1. Thirty-
six of the 42 patients in the H. pylori resistant group, and 40 of the 50 patients in the newly H.
pylori diagnosed group were treated according to the protocol. The remaining patients refused
to participate in the treatment protocol.
Table 1. Baseline characteristics of the four different study groups. Values are presented as number (ratio (%)) or mean (95% CI). For further details, see text.
H. pylori patient groups Resistant n = 42 Newly diagnosed n = 50 Eradicated n = 61 Never infected n = 32
Age (years) 59 (56–63) 51 (46–56) 62 (59–65) 52 (47–57)
BMI (kg/m2) 26 (25–28) 27 (25–28) 26 (25–28) 25 (24–27)
Sex
Female 26 (62%) 28 (56%) 31 (51%) 21 (66%)
Male 16 (38%) 22 (44%) 30 (49%) 11 (34%)
Tobacco use
Non-smoker 30 (71%) 40 (80%) 35 (57%) 21 (68%)
Current smoker 12 (29%) 10 (20%) 26 (43%) 10 (32)
Non-snuffer 42 (100%) 47 (94%) 60 (98%) 30 (97%)
Snuffer 0 (0%) 3 (6%) 1 (2%) 1 (3%)
Medication use
H2RA 8 (19%) 4 (8%) 8 (13%) 2 (7%)
PPI 17 (40%) 7 (14%)� 23 (38%) 13 (42%)
PI 6 (14%) 7 (14%) 13 (21%) 3 (10%)
NSAID 3 (7%) 2 (4%) 11 (18%) 6 (19%)
Except for PPI, no significant differences were detected between groups (p<0.017, Mann-Whitney non-parametric test with Bonferroni correction, compared to H.
pylori resistance group). Abbreviations: PPI: Proton pump inhibitor, PI: Platelet inhibitor, NSAID: Non-steroidal anti-inflammatory drug.
https://doi.org/10.1371/journal.pone.0238944.t001
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Upper GI symptoms
The upper GI symptoms registered as total score of five dimensions (abdominal pain, indiges-
tion, diarrhea, reflux and constipation [15,16]) in the five patient groups are shown in Table 2.
The global test showed a p-value of 0.002 indicating a statistical significant difference in upper
gastrointestinal symptom burden between the groups There was a significant difference in
upper gastrointestinal symptom burden between groups. For the five dimensions of upper GI
symptoms, the H. pylori resistant group showed a significant increased score compared to
both the group of newly diagnostic H. pylori and H. pylori eradicated patients, but not to
patients never infected with H. pylori (Table 2, Fig 1). In Table 2 each of the five symptom
dimensions are also shown. No significant differences between the groups were observed
regarding the prevalence of reflux syndrome and dyspepsia (Table 3).
Functional bowel symptoms
Functional bowel symptoms (FBS) based on GSRS dimensions that closest resemble irritable
bowel syndrome according to Wicklund et al [19] are shown in Table 3 and Fig 2. FBS was more
frequent observed in the H. pylori resistant group than in the newly diagnosed H. pylori and the
H. pylori eradicated patients, but not when compared to patients never H. pylori infected.
Endoscopic characteristics
The endoscopic findings are shown in Table 4. Gastritis was more prevalent in H. pylori posi-
tive patient groups compared to the H. pylori treated group and the H. pylori patient groups
never infected group. Moreover, no significant differences were observed between the two
infected H. pylori positive groups. No patients in any group had duodenal ulcer.
Table 2. Baseline Gastrointestinal Symptoms Rating Scale (GSRS) of five dimensions of upper gastrointestinal symptoms in the four study groups.
H. pylori patient groups Resistant Newly diagnosed Eradicated Never infected
Abdominal pain 3.0 (2.6–3.4) 2.8 (2.4–3.1) 2.3 (2.0–2.5)�� 3.3 (2.7–3.8)
Indigestion 3.1 (2.7–3.6) 2.3 (2.0–2.7)� 2.4 (2.1–2.6) 3.0 (2.8–3.8)
Diarrhoea 2.0 (1.5–2.4) 1.6 (1.3–2.0) 1.7 (1.5–2.0) 2.6 (1.9–3.3)��
Reflux 2.7 (2.2–3.2) 2.0 (1.7–2.3) 2.2 (1.9–2.4) 2.3 (1.8–2.8)
Constipation 2.2 (1.8–2.5) 1.7 (1.3–2.0)� 1.7 (1.4–2.0)� 2.1 (1.5–2.6)
Upper GI symptoms1 2.5 (2.3–2.8) 2.0 (1.7–2.2)� ,��� 2.1 (1.9–2.3)� 2.6 (2.2–2.9)
Values are presented as mean (95% CI).
1) Upper GI symptoms, calculated by mean sum of the 5 dimensions of the GSRS score as described in Materials and Methods.
�) compared to H. pylori resistant
��) compared to newly diagnosed H. pylori
���) compared to never H. pylori infected. p<0.017, Mann-Whitney U non-parametric test compared to H. pylori resistant group, with Bonferroni correction.
https://doi.org/10.1371/journal.pone.0238944.t002
Table 3. Prevalence in the four study groups of functional bowel symptoms, reflux syndrome and dyspepsia as defined in Materials and Methods.
H. pylori patient groups Resistant Newly diagnosed Eradicated Never infected
FBS (n = 174) 28 (74%) 23 (48%)� 20 (34%)� 21 (72%)
Reflux syndrome (n = 182) 32 (78%) 29 (59%) 40 (66%) 23 (74%)
Dyspepsia (n = 184) 38 (90%) 46 (92%) 50 (82%) 30 (97%)
Numbers represent n (% of group). FBS: Functional bowel symptoms
�) p<0.017, Chi-Square test compared to H pylori resistant group, with Bonferroni correction.
https://doi.org/10.1371/journal.pone.0238944.t003
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Fig 1. Baseline Gastrointestinal Symptoms Rating Scale (GSRS) scores in the five dimensions of upper
gastrointestinal symptoms in the four different H. pylori groups. P-values represent comparison to the H. pylori
resistant group.
https://doi.org/10.1371/journal.pone.0238944.g001
Fig 2. Functional bowel symptoms (FBS) based on baseline Gastrointestinal Symptoms Rating Scale (GSRS) of 5
dimensions as described in Materials and Methods in the four different H. pylori groups. P-values represent
comparison to the H. pylori resistant group.
https://doi.org/10.1371/journal.pone.0238944.g002
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Histological characteristics
In Table 5, the Sydney histological scores are presented. The treatment resistant H- pylori
patients had a lower score than the newly diagnosed H. pylori patient group. Moreover, the
group of H. pylori eradicated patients and never H. pylori patient groups infected had signifi-
cantly lower score that the two other groups.
In Table 6 the Ki-67 index and presence of atrophy in gastric biopsies are evaluated. For
both parameters no significant differences were observed between the two H. pylori patient
groups infected groups including the subgroups before and after eradication (total of 4 sub-
groups). Moreover, when comparisons were performed between each of these 4 groups to the
group of previously H. pylori eradicated and the group never infected significant differences
were observed and especially for Ki-67 as shown in Table 6. Significant difference between the
H. pylori eradicated and never infected group was also shown in Ki-67 (medium-high). To be
noted, there was no increased atrophy in the H. pylori resistant group compared to the newly
diagnosed H, pylori patient groups diagnosed group nor the H. pylori patient groups eradicated
group. Finally, atrophy was slightly reduced after H. pylori patient groups eradication in the
two H. pylori patient groups infected groups but not at significant levels.
H. pylori patient groups, diagnostics
The H. pylori diagnostics (at least one positive test of H. pylori-urease test and a positive histo-
logical test of H. pylori) in the four different H. pylori patient groups groups are shown in
Table 7. Histological H. pylori patient groups detection in biopsies was positive in a few biop-
sies with negative urease test.
H. pylori patient groups, treatment
Thirty-six of the 42 patients in the H. pylori patient groups resistant group and 40 of the 50
patients in the newly H. pylori patient groups diagnosed group were treated according to the
protocol. The Sydney score was significantly reduced in both treatment groups (Table 5)
Table 4. Endoscopic characteristics of the four study groups.
H. pylori patient groups Resistant Newly diagnosed Eradicated Never infected
Normal 5 (12%) 6 (12%) 18 (30%) 18 (56%)
Gastritis 25 (60%) 31 (62%) 19 (31%)� 5 (16%)�
Esophagitis 3 (7%) 3 (6%) 3 (5%) 2 (6%)
Gastric Ulcer 1 (2%) 0 0 1 (3%)
Duodenitis 8 (19%) 9 (18%) 16 (26%) 4 (13%)
Hiatal hernia 0 1 (2%) 5 (8%) 2 (6%)
Values are presented as numbers (%).
�) p <0.017, Chi Square test with Bonferroni correction, compared to patients with active infection
https://doi.org/10.1371/journal.pone.0238944.t004
Table 5. Sydney histological scores in gastric biopsies from the four study groups.
H. pylori patient groups Resistant Newly diagnosed Eradicated Never infected
All 2.3 (1.1) n = 42 3.2 (1.0)� n = 49 0.6 (0.9)� ,�� n = 61 0.4 (0.8)� ,�� n = 32
Before treatment 2.3 (2.0–2.7) n = 36 3.2 (2.9–3.3) n = 40 - -
After treatment 1.1 (0.8–1.4) ��� n = 36 1.4 (0.9–1.8)��� n = 40 - -
The results are mean (SD) or mean (95% CI). Sydney score: Leucocyte infiltrate (total of neutrophils and monocytes) in gastric mucosa.
�), ��) and ���): Significantly different (p<0.017 with Bonferroni correction) from �) H. pylori resistant, ��) newly diagnosed and ���) before treatment.
https://doi.org/10.1371/journal.pone.0238944.t005
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Discussion
We have made comparisons between a cohort of patients with treatment- resistance H. pylori
infection and patients who underwent gastroscopy due to upper gastrointestinal complaints
and who were further sub-grouped into “newly diagnosed H. pylori patient groups infection”,
“previously H. pylori patient groups eradicated” and “never H. pylori patient groups infected”.
The treatment-resistant cohort had a higher upper gastrointestinal symptom score, more func-
tional bowel symptoms (FBS), and a reduced histological inflammation (Sydney) score com-
pared to the newly diagnosed H. pylori patient groups group. Levofloxacin in combination
with amoxicillin and omeprazole was highly effective in the eradication of H. pylori in the
resistant patients and even more effective compared to newly H. pylori diagnosed patients
treated with a conventional eradication regime (amoxicillin, clarithromycin and omeprazole).
As far as we know this is the first broad characterization of patients with resistant H. pylori
infection. Finally, the two non-infected groups had low Sydney scores, but only the never
infected group–also defined as “true” functional dyspepsia–scored high both for upper gastro-
intestinal symptoms and FBS. This may imply two different clinical phenotypes.
The upper gastrointestinal symptom score was higher in the H. pylori resistant group com-
pared to the group of newly diagnosed H. pylori infection, and even more increased compared
to the previously (>5 years) eradicated H. pylori group. This score is based on the baseline Gas-
trointestinal Symptoms Rating Scale (GSRS) of five dimensions of upper gastrointestinal
symptoms: abdominal pain, indigestion, reflux, diarrhoea and constipation, and the total score
based on a study of patients referred to upper endoscopy for dyspepsia as validated in previous
reports.[15,16] As seen for reflux in Table 2 and for reflux syndrome in Table 3 no significant
differences were observed between the groups with and without active H. pylori infection. The
role of H. pylori in reflux is also somewhat controversial, as both the presence and the absence
of an association have been reported.[21–23] In a population-based study from our research














Low 3/42� ,�� 8/35� 6/45� 7/40� 18/58� 14/28
Medium-high 39/42� ,�� 27/35� 39/45� 33/40� 42/58� 14/28
Atrophy
Normal 30/42 32/37 41/52 35/40 55/60 27/28
Low-high 12/42� ,�� 5/37 11/52 5/40 5/60 1/28
Numbers are ratios of scored biopsy specimens within each group.
�) and ��): Significant different (p<0.017 with Bonferroni correction) from �) from: �) Never infected ��) Eradicated. There were no significant differences between
other groups.
https://doi.org/10.1371/journal.pone.0238944.t006
Table 7. H pylori diagnostics in the four study groups.
H. pylori patient groups All groups Resistant Newly diagnosed Eradicated Never infected
Positive urease test 82/184 (45%) 33/42 (79%) 49/49 (100%) 0/61 (0) 0/32 (0)
Positive histology 89/184 (48%) 40/42 (95%) 49/50 (100%) 0/61 (0) 0/32 (0)
At least one of two 92/184 (50%) 42/42 (100%) 50/50 (100%) 0/61 (0) 0/32 (0)
Values are presented as ratios (%).
https://doi.org/10.1371/journal.pone.0238944.t007
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group, H. pylori was protective against reflux symptoms in men.[24] The functional bowel
symptom score was also increased in the H. pylori resistant group compared to the group of
newly diagnosed H. pylori infection and even more increased compared to the previously H.
pylori eradicated group. The association between H. pylori infection and IBS is not settled. H.
pylori infection has been shown to be a risk factor for IBS in one study, but not in three other
reports.[25–28] There are, however, no larger, population-based studies that have addressed
this issue except from that reported by Breckan et al. in 2012 where H. pylori infection was not
found to be associated with functional bowel symptoms.[20]
We used a combination of levofloxacin and amoxicillin in the second line triple therapy of
H. pylori. This antibiotic combination has been reported to be successful in second-line H.
pylori eradication with an efficacy of some 90%, as seen in our study.[11,13] An even higher
score has been shown in sequential or concomitant use of levofloxacin, with a cumulative ther-
apeutic efficacy of as high as 97.8% in second line therapy.[10,12] Despite the highly efficacy of
levofloxacin and amoxicillin in second line triple therapy of H. pylori in our and other studies,
it should be noticed that antibiotic resistance against H. pylori is an increasing worldwide
health problem that now also includes levofloxacin resistance.[29] Therefore, the choice of
antibiotics should be carefully selected to prevent antimicrobial resistance, and should be
based on antibiotic resistance testing, including testing for levofloxacin according to the 2017
Maastricht Guidelines.[10]
In our study, gastric atrophy was more pronounced in the treatment resistant H. pylori
group compared to the group never infected with H. pylori. This is in agreement with other
reports including a meta-analysis by Adamu et al.[30] Moreover, H. pylori eradication reduced
gastric atrophy as shown, yet only slightly. This may be explained by a short observation time
after eradication (3 months). A meta-analysis by Rokka showed that H. pylori eradication
indeed reduced gastric atrophy,[31] which implies that eradication of H. pylori in apparent
treatment resistant cases should be given more priority in order to reduce which a proposed
gastric precancerous condition.[32]
Of interest was the cohort of patients never infected with H. pylori—a group defined as
“true” functional dyspepsia according the Maastricht V/Florence Consensus Report from
2017.[10] As expected, these patients presented both upper gastrointestinal symptoms and
functional bowel symptoms (Tables 1 and 2, Figs 1 and 2) on a level with the H. pylori resistant
patients. Conversely, the previously H. pylori eradicated patients had low Sydney and endo-
scopic gastric scores comparable to the never H. pylori infected, but this formerly infected
group had low upper gastrointestinal symptom and functional bowel symptom scores. This
may indicate that H. pylori infection, when being treatment resistant and/or infection being
longstanding, may precipitate functional abdominal disorders including dyspepsia. One could
propose that a successful eradication of H. pylori infection would reduce such gastrointestinal
complaints. However, this awaits further studies.
The strength of this study is that we have performed a broad characterization of a H. pylori
treatment resistant group and made comparisons to relevant patient groups with upper gastro-
intestinal symptoms. Moreover, we have tested for potential confounders when comparing
groups of patients. The weakness of the study is that a follow-up study (>5 years after H. pylori
eradication) has to be performed to characterize potential functional gastrointestinal
symptoms.
In conclusion, patients with treatment-resistant H. pylori infection had more upper gastro-
intestinal symptoms and functional bowel symptoms, whereas the Sydney score was lower
than in patients with newly diagnosed H. pylori infection. A triple combination of levofloxacin,
amoxicillin and omeprazole showed a high efficacy in eradicating the infection.
PLOS ONE Helicobacter pylori resistance
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